Related Experiment Video

Updated: Jul 16, 2026

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
06:04

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

Research progress on detection technologies for Mycoplasma pneumoniae

Huanhuan Wu1,2, Fang Jiang1,2, Siyu Tian3

  • 1Clinical Laboratory Center, Central Hospital of Dalian University of Technology, Dalian, 116044, China.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|July 15, 2026
PubMed

Insights

Rapid diagnostics for Mycoplasma pneumoniae (M. pneumoniae) are crucial due to rising infections and macrolide resistance. This review covers evolving detection methods, from traditional to advanced molecular techniques, for better community-acquired pneumonia (CAP) management.

Area of Science:

  • Medical Microbiology
  • Diagnostic Technologies
  • Infectious Diseases

Background:

  • Mycoplasma pneumoniae causes community-acquired pneumonia (CAP), especially in children and adolescents.
  • A global resurgence of M. pneumoniae infections and macrolide-resistant strains (MRMP) necessitates advanced diagnostics.

Purpose of the Study:

  • To systematically review the evolution of M. pneumoniae diagnostic technologies.
  • To analyze emerging platforms for point-of-care testing (POCT) and antimicrobial resistance profiling.

Main Methods:

  • Review of traditional methods (culture, serology).
  • Analysis of modern molecular techniques (isothermal amplification, CRISPR/Cas, microfluidics, biosensors).
  • Exploration of AI integration for automated diagnostics.

Main Results:

  • Technological advancements show promise for rapid and precise M. pneumoniae detection.
  • Emerging platforms offer potential for point-of-care applications and resistance profiling.
  • Challenges include differentiating active infection from colonization and cost-effectiveness.

Conclusions:

  • The future of M. pneumoniae diagnostics involves integrating diverse biotechnologies with AI for intelligent 'sample-to-answer' systems.
  • Optimizing clinical antimicrobial stewardship is a key goal for advanced diagnostic solutions.
  • Further development is needed to address current diagnostic limitations and improve patient outcomes.
Keywords:
Mycoplasma pneumoniaeDiagnosisIsothermal amplificationPoint-of-care testing (POCT)

More Related Videos

Optimized PCR-based Detection of Mycoplasma06:01

Optimized PCR-based Detection of Mycoplasma

Published on: June 20, 2011

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Rapid Identification of Pathogens01:25

Rapid Identification of Pathogens

MALDI-TOF MS has transformed clinical microbiology by offering a rapid and reliable method for pathogen identification. The traditional approach to microbial identification typically involves time-consuming culture techniques and biochemical tests, which can delay the initiation of appropriate antimicrobial therapy. MALDI-TOF MS avoids these delays by using characteristic ribosomal protein mass patterns of microbial cells, enabling accurate species-level identification within minutes.Principle...